Alpha 2.0
Login Register
» Authors » Maud Velev

Maud Velev

Explore the profile of Maud Velev including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 26
Followers 0
Related Specialties
Oncology
Urology
Chemistry
Top 10 Co-Authors
Laurence Albiges
Constance Thibault
Stephane Oudard
Ronan Flippot
Philippe E Spiess
Michael R Harrison
Patricia Pautier
Jacob Taylor
David Kryza
Giandomenico Roviello
Published In
Eur J Cancer
Rev Prat
J Natl Cancer Inst
Pharmaceuticals (Basel)
BJU Int
Affiliations
Soon will be listed here.
Recent Articles
1.
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study
Flippot R, Telli T, Velev M, Flechon A, De Vries-Brilland M, Turpin L, et al.
Eur Urol Oncol . 2024 Apr; 7(5):1132-1140. PMID: 38664139
Background: Both cabazitaxel and lutetium-177 prostate-specific membrane antigen (Lu-PSMA) improve survival in metastatic castration-resistant prostate cancer (mCRPC) after an androgen receptor pathway inhibitor and docetaxel, but there are limited data...
2.
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer
von Deimling M, Mertens L, Furrer M, Li R, Tendijck G, Taylor J, et al.
BJU Int . 2024 Mar; 134(1):119-127. PMID: 38470089
Objective: To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or...
3.
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
El Zarif T, Nassar A, Pond G, Zhuang T, Master V, Nazha B, et al.
J Natl Cancer Inst . 2023 Aug; 115(12):1605-1615. PMID: 37563779
Background: Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors....
4.
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, et al.
Eur J Cancer . 2023 Feb; 182:66-76. PMID: 36746010
Introduction: Bone metastases (BM) in renal cell carcinoma (RCC) are associated with a poor prognosis based on retrospective studies evaluating antiangiogenic agents. Few data are available regarding immune checkpoint inhibitors...
5.
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors
Velev M, Baroudjian B, Pruvost R, De Martin E, Laparra A, Babai S, et al.
Eur J Cancer . 2022 Dec; 179:28-47. PMID: 36473326
Background: Generalised oedema was occasionally reported associated with immune checkpoint inhibitors (ICPIs). The purpose of this study is to investigate immune-related generalised oedema (ir-GE) drug related to ICPI, through frequency,...
6.
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
Velev M, Puszkiel A, Blanchet B, De Percin S, Delanoy N, Medioni J, et al.
Pharmaceuticals (Basel) . 2021 Aug; 14(8). PMID: 34451901
Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of early significant adverse events (SAE). We...
7.
[Treatment of metastatic prostate cancer: what recent progress?]
Oudard S, Velev M, Belhadj Y, Vano Y, Thibault C
Rev Prat . 2019 Mar; 68(7):707-712. PMID: 30869315
No abstract available.